Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
4.420
-0.190 (-4.12%)
At close: Aug 13, 2025, 4:00 PM
4.740
+0.320 (7.24%)
Pre-market: Aug 14, 2025, 9:05 AM EDT
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2024. The number of employees decreased by 9 or -45.00% compared to the previous year.
Employees
11
Change (1Y)
-9
Growth (1Y)
-45.00%
Revenue / Employee
n/a
Profits / Employee
-$2,231,227
Market Cap
12.63M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CLRB News
- 2 hours ago - Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 days ago - Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 - GlobeNewsWire
- 6 weeks ago - Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 6 weeks ago - Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering - GlobeNewsWire
- 7 weeks ago - Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement - GlobeNewsWire
- 7 weeks ago - Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) - GlobeNewsWire
- 2 months ago - Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - GlobeNewsWire
- 2 months ago - Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - GlobeNewsWire